Xiao Jing, Guo Jia, Zhao Zhi-hong, Jin Yun-feng, Liu Dong, Zhao Zhan-zheng
Department of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Department of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Email:
Zhonghua Nei Ke Za Zhi. 2013 Dec;52(12):1048-52.
To investigate the effects of cyclooxygenase-2 (COX-2) inhibitor on peritoneal lymphangiogenesis and peritoneum function in uremic rat.
Uremic rats treated by peritoneal dialysis were intragastric administration celecoxib.Structures of peritoneum, peritoneal function, peritoneal lymphatic vessel density (LVD) were detected in every group. The mRNA of vascular endothelial growth factor-C (VEGF-C), lymphatic vessel endothelial hyaluronan receptor-1(LYVE-1) and COX-2 were tested by RT-PCR. The protein expressions of LYVE-1,VEGF-C, COX-2 were tested by western blot.
With the extension of the duration of dialysis, the peritoneum thickness was increasing, inflammatory cell infiltrated obviously, ultrafiltration volume decreased significantly. But the celecoxib could increase ultrafiltration volume and reduce the glucose transport rate (P < 0.05) . Compared with the normal group, the levels of LVD, COX-2,VEGF-C, and LYVE-1 mRNA and protein were significantly up-regulated in uremic and dialysis groups (P < 0.05). Compared with the uremic dialysis group, the levels of LVD, COX-2,VEGF-C and LYVE-1 mRNA and protein were significantly down-regulated in the celecoxib group. There was a positive correlation between COX-2 and VEGF-C, LVD in protein levels, as well as VEGF-C and LVD(all P values<0.05).
Hyper glucose dialysis solution and uremic condition could up-regulate the expression of COX-2,VEGF-C, LYVE-1 in gene and protein level and stimulate lymphangiogenesis. COX-2 inhibitor could delay the change of peritoneal structures and function. COX-2 inhibitor could prevent the lymphangiogenesis in uremic rat treated by peritoneal dialysis, which might down-regulate the expression of VEGF-C by COX-2 depended manner.
探讨环氧化酶-2(COX-2)抑制剂对尿毒症大鼠腹膜淋巴管生成及腹膜功能的影响。
对接受腹膜透析的尿毒症大鼠进行塞来昔布灌胃。检测每组大鼠的腹膜结构、腹膜功能、腹膜淋巴管密度(LVD)。采用逆转录聚合酶链反应(RT-PCR)检测血管内皮生长因子-C(VEGF-C)、淋巴管内皮透明质酸受体-1(LYVE-1)和COX-2的mRNA。采用蛋白质免疫印迹法检测LYVE-1、VEGF-C、COX-2的蛋白表达。
随着透析时间的延长,腹膜厚度增加,炎性细胞明显浸润,超滤量显著下降。但塞来昔布可增加超滤量并降低葡萄糖转运率(P<0.05)。与正常组相比,尿毒症组和透析组的LVD、COX-2、VEGF-C及LYVE-1 mRNA和蛋白水平均显著上调(P<0.05)。与尿毒症透析组相比,塞来昔布组的LVD、COX-2、VEGF-C及LYVE-1 mRNA和蛋白水平均显著下调。COX-2与VEGF-C、LVD在蛋白水平呈正相关,VEGF-C与LVD也呈正相关(所有P值<0.05)。
高糖透析液及尿毒症状态可在基因和蛋白水平上调COX-2、VEGF-C、LYVE-1的表达并刺激淋巴管生成。COX-2抑制剂可延缓腹膜结构和功能的改变。COX-2抑制剂可抑制尿毒症大鼠腹膜透析后的淋巴管生成,可能通过COX-2依赖方式下调VEGF-C的表达。